Moneycontrol

Budget 2023Budget 2023

PARTNERS

  • Tata AIA Life Insurance
  • Hafele
  • Motilal Oswal
  • SMC Global Securities Limited
  • SBI Life
  • DSP Mutual Fund
Upcoming Event : LeapToUnicorn - mentoring, networking and fundraising for startups. Register now

Lupin readies for a mega specialty drug play with $1-bn war chest

Lupin on Wednesday has agreed to buy US-based Symbiomix Therapeutics for USD 150 million. The drug maker will be doing several deals in the coming quarters.

October 13, 2017 / 07:43 AM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Moneycontrol News
Lupin, India’s second largest drug maker by sales, said its balance sheet allows it to leverage up to one billion dollars as war chest for acquisitions as it aspires to build a specialty branded business in US focusing on women’s health.

“We have the capacity to lever our balance sheet up to a billion dollars, but that doesn't necessarily mean that we are going to spend one billion dollars in one single tranche, it is obviously going to be spread across several tranches,” said Ramesh Swaminathan, Chief Financial Officer of Lupin.

Lupin on Wednesday said it has agreed to buy US-based Symbiomix Therapeutics for USD 150 million. The acquisition gives Lupin control over Symbiomix’s lead product, Solosec oral granules, for the treatment of bacterial vaginosis in adult women. In September, the USFDA approved marketing of Solosec with 10-year exclusivity.

The Mumbai-based drug maker said it will be doing several such deals in the coming quarters.